http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Xiaomeng Yue,Jane M. Pruemer,Ana L. Hincapie,Ziyad S. Almalki,Jeff J. Guo 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.4
Objective: This study estimated nationally representative medical expenditures ofgynecologic cancers, described treatment patterns and assessed key risk factors associatedwith the economic burden in the United States. Methods: A retrospective repeated measures design was used to estimate the effect ofgynecologic cancers on medical expenditures and utilization among women. Data wereextracted from the Medical Expenditure Panel Survey (weighted sample of 609,787 US adults)from 2007 to 2014. Using the behavioral model of health services utilization, characteristicsof cancer patients were examined and compared among uterine, cervical, and ovarian cancerpatients. Multivariable linear regression models were conducted on medical expenditure witha prior logarithmic transformation. Results: The estimated annual medical expenditure attributed to gynecologic cancers was$3.8 billion, with an average cost of $6,293 per patient. The highest annual cost per personwas ovarian cancer ($13,566), followed by uterine cancer ($6,852), and cervical cancer($2,312). The major components of medical costs were hospital inpatient stays (53%, $2.03billion), followed by office-based visits (15%, $559 million), and outpatient visits (13%, $487million). Two key prescription expenditures were antineoplastic hormones (10.3%) andanalgesics (9.2%). High expenditures were significantly associated with being a marriedwoman (p<0.001), having private health insurance (p<0.001), being from a low- and middle income family (p<0.001), or living in the Midwest or the South (p<0.001). Conclusion: The key risk factors and components were well described for the economicburden of gynecologic cancers. With a growing population of cancer patients, efforts toreduce the burden of gynecologic cancers are warranted.